Use of voriconazole in a patient with aspergilloma caused by an itraconazole-resistant strain of Aspergillus fumigatus

被引：18
作者：
Dannaoui, E. [1 ]
Garcia-Hermoso, D.
Naccache, J. M.
Meneau, I.
Sanglard, D.
Bouges-Michel, C.
Valeyre, D.
Lortholary, O.
机构：
[1] Inst Pasteur, Ctr Natl Reference Mycol & Antifong, Unite Mycol Mol, CNRS,FRE2849, F-75724 Paris 15, France
[2] Univ Paris Descartes, Fac Med, AP HP, Hop European Georges Pompidou,Unite Parasitol Myc, F-75015 Paris, France
[3] Hop Avicenne, Serv Pneumol, F-93009 Bobigny, France
[4] Univ Hosp Lausanne, Inst Microbiol, CH-1011 Lausanne, Switzerland
[5] Hop Avicenne, Lab Parasitol Mycol, F-93009 Bobigny, France
[6] Univ Paris Descartes, Fac Med, Hop Necker Enfants Malad, AP HP,Serv Malad Infect & Trop, F-75743 Paris 15, France
来源：
JOURNAL OF MEDICAL MICROBIOLOGY | 2006年 / 55卷 / 10期
关键词：
D O I：
10.1099/jmm.0.46639-0
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
The case is reported of a patient with cavitary sarcoidosis complicated by an aspergilloma caused by an itraconazole-resistant strain of Aspergillus fumigatus, who was treated with voriconazole. The authors suggest that susceptibility testing of A. fumigatus strains is of value during long-term therapy with itraconazole, and that voriconazole may be a good option for treatment of patients infected with itraconazole-resistant strains of A. fumigatus.
引用
收藏
页码：1457 / 1459
页数：3
相关论文
共 14 条
[1]   In vitro susceptibility of respiratory isolates of Aspergillus species to itraconazole and amphotericin B. Acquired resistance to itraconazole [J].
Chryssanthou, E .
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1997, 29 (05) :509-512
[2]   Acquired itraconazole resistance in Aspergillus fumigatus [J].
Dannaoui, E ;
Borel, E ;
Monier, MF ;
Piens, MA ;
Picot, S ;
Persat, F .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 47 (03) :333-340
[3]   Itraconazole resistance in Aspergillus fumigatus [J].
Denning, DW ;
Venkateswarlu, K ;
Oakley, KL ;
Anderson, MJ ;
Manning, NJ ;
Stevens, DA ;
Warnock, DW ;
Kelly, SL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (06) :1364-1368
[4]   Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.:: NCCLS collaborative evaluation [J].
Espinel-Ingroff, A ;
Bartlett, M ;
Chaturvedi, V ;
Ghannoum, M ;
Hazen, KC ;
Pfaller, MA ;
Rinaldi, M ;
Walsh, TJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) :1828-1835
[5]   Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis [J].
Herbrecht, R ;
Denning, DW ;
Patterson, TF ;
Bennett, JE ;
Greene, RE ;
Oestmann, JW ;
Kern, WV ;
Marr, KA ;
Ribaud, P ;
Lortholary, O ;
Sylvester, R ;
Rubin, RH ;
Wingard, JR ;
Stark, P ;
Durand, C ;
Caillot, D ;
Thiel, E ;
Chandrasekar, PH ;
Hodges, MR ;
Schlamm, HT ;
Troke, PF ;
de Pauw, B .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (06) :408-415
[6]   Substitutions at methionine 220 in the 14α-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs [J].
Mellado, E ;
Garcia-Effron, G ;
Alcazar-Fuoli, L ;
Cuenca-Estrella, M ;
Rodriguez-Tudela, JL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (07) :2747-2750
[7]   Azole cross-resistance in Aspergillus fumigatus [J].
Mosquera, J ;
Denning, DW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (02) :556-557
[8]   Increased expression of a novel Aspergillus fumigatus ABC transporter gene, atrF, in the presence of itraconazole in an itraconazole resistant clinical isolate [J].
Slaven, JW ;
Anderson, MJ ;
Sanglard, D ;
Dixon, GK ;
Bille, J ;
Roberts, IS ;
Denning, DW .
FUNGAL GENETICS AND BIOLOGY, 2002, 36 (03) :199-206
[9]   The clinical spectrum of pulmonary aspergillosis [J].
Soubani, AO ;
Chandrasekar, PH .
CHEST, 2002, 121 (06) :1988-1999
[10]   Practice guidelines for diseases caused by Aspergillus [J].
Stevens, DA ;
Kan, VL ;
Judson, MA ;
Morrison, VA ;
Dummer, S ;
Denning, DW ;
Bennett, JE ;
Walsh, TJ ;
Patterson, TF ;
Pankey, GA .
CLINICAL INFECTIOUS DISEASES, 2000, 30 (04) :696-709
12